Literature DB >> 25044787

Online registry for mutations in hereditary amyloidosis including nomenclature recommendations.

Dorota M Rowczenio1, Islam Noor, Julian D Gillmore, Helen J Lachmann, Carol Whelan, Philip N Hawkins, Laura Obici, Per Westermark, Gilles Grateau, Ashutosh D Wechalekar.   

Abstract

Hereditary systemic amyloidosis comprises a group of rare monogenic diseases inherited in an autosomal dominant fashion. It is associated with mutations in genes encoding eight different proteins, including transthyretin, apolipoprotein AI, apolipoprotein AII, lysozyme, fibrinogen A α-chain, cystatin C, gelsolin and beta-2-microglobulin. With support from the EU FP6 EURAMY project we have designed an online registry of genes and mutations in hereditary amyloidosis including their associated clinical phenotypes, with a view to having a single free online portal for the collection and distribution of this information. Users can search the registry by either mutation, phenotype or authors who have published or submitted mutations. It provides a submission form for reporting newly identified mutations. We also wanted to introduce nomenclature which complies with recommendations set out by Human Genome Variation Society and HUGO Gene Nomenclature Committee for description of new and known genetic variants. We hope this registry would be a useful and convenient tool for the medical and scientific community.
© 2014 WILEY-LISS, INC.

Entities:  

Keywords:  Hereditary amyloidosis; amyloidogenic and non-amyloidogenic mutations; online registry

Mesh:

Year:  2014        PMID: 25044787     DOI: 10.1002/humu.22619

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  68 in total

1.  VLITL is a major cross-β-sheet signal for fibrinogen Aα-chain frameshift variants.

Authors:  Cyrille Garnier; Fatma Briki; Brigitte Nedelec; Patrick Le Pogamp; Ahmet Dogan; Nathalie Rioux-Leclercq; Renan Goude; Caroline Beugnet; Laurent Martin; Marc Delpech; Frank Bridoux; Gilles Grateau; Jean Doucet; Philippe Derreumaux; Sophie Valleix
Journal:  Blood       Date:  2017-10-31       Impact factor: 22.113

Review 2.  Fibrinogen alpha amyloidosis: insights from proteomics.

Authors:  Jessica Chapman; Ahmet Dogan
Journal:  Expert Rev Proteomics       Date:  2019-08-28       Impact factor: 3.940

3.  Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease.

Authors:  Elena S Klimtchuk; Tatiana Prokaeva; Nicholas M Frame; Hassan A Abdullahi; Brian Spencer; Surendra Dasari; Haili Cui; John L Berk; Paul J Kurtin; Lawreen H Connors; Olga Gursky
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-25       Impact factor: 11.205

4.  Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR).

Authors:  Björn Pilebro; Sandra Arvidsson; Per Lindqvist; Torbjörn Sundström; Per Westermark; Gunnar Antoni; Ole Suhr; Jens Sörensen
Journal:  J Nucl Cardiol       Date:  2016-09-19       Impact factor: 5.952

Review 5.  Noncerebral Amyloidoses: Aspects on Seeding, Cross-Seeding, and Transmission.

Authors:  Gunilla T Westermark; Marcus Fändrich; Katarzyna Lundmark; Per Westermark
Journal:  Cold Spring Harb Perspect Med       Date:  2018-01-02       Impact factor: 6.915

6.  Structure-Based Small Molecule Modulation of a Pre-Amyloid State: Pharmacological Enhancement of IAPP Membrane-Binding and Toxicity.

Authors:  Abhinav Nath; Diana E Schlamadinger; Elizabeth Rhoades; Andrew D Miranker
Journal:  Biochemistry       Date:  2015-05-22       Impact factor: 3.162

7.  The amyloidogenic V122I transthyretin variant in elderly black Americans.

Authors:  C Cristina Quarta; Joel N Buxbaum; Amil M Shah; Rodney H Falk; Brian Claggett; Dalane W Kitzman; Thomas H Mosley; Kenneth R Butler; Eric Boerwinkle; Scott D Solomon
Journal:  N Engl J Med       Date:  2015-01-01       Impact factor: 91.245

8.  Early-phase myocardial uptake intensity of 99mTc-HMDP vs 99mTc-DPD in patients with hereditary transthyretin-related cardiac amyloidosis.

Authors:  Mukedaisi Abulizi; Anne-Ségolène Cottereau; Aziz Guellich; Stéphanie Vandeventer; Arnault Galat; Axel Van Der Gucht; Violaine Plante-Bordeneuve; Jean-Luc Dubois-Randé; Diane Bodez; Jean Rosso; Thibaud Damy; Emmanuel Itti
Journal:  J Nucl Cardiol       Date:  2016-11-01       Impact factor: 5.952

9.  Transthyretin variants with improved inhibition of β-amyloid aggregation.

Authors:  Parth Mangrolia; Dennis T Yang; Regina M Murphy
Journal:  Protein Eng Des Sel       Date:  2016-04-19       Impact factor: 1.650

Review 10.  Updates in Cardiac Amyloidosis Diagnosis and Treatment.

Authors:  Lily K Stern; Michelle M Kittleson
Journal:  Curr Oncol Rep       Date:  2021-03-16       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.